Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Merosin-deficient congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Merosin-deficient congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Merosin-deficient congenital muscular dystrophy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Read →
Multi-minicore disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Multi-minicore disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Multi-minicore disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Bethlem myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Bethlem myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Bethlem myopathy indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Ullrich congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Ullrich congenital muscular dystrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Ullrich congenital muscular dystrophy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →
Multimeric Biotherapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Multimeric Biotherapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Multimeric Biotherapeutics, Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Central core disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Central core disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Central core disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Nemaline myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Nemaline myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Nemaline myopathy indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Polymyositis overlap syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Polymyositis overlap syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Polymyositis overlap syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Myotonic dystrophy type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Myotonic dystrophy type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Myotonic dystrophy type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Congenital myotubular myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Congenital myotubular myopathy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Congenital myotubular myopathy strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Myofascial pain syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Myofascial pain syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Myofascial pain syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Complex regional pain syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Complex regional pain syndrome type 2 Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Complex regional pain syndrome type 2 strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →